Collaborations & Alliances
Related Searches:
Filter by:
July 25, 2008
Symyx Technologies, Inc. launched its new client-directed and collaborative research services for Life Sciences. These services allow clients to access Symyx’s installed base of parallel experimentation and testing capabilities through packaged…
Read More »
July 17, 2008
Genzyme and PTC Therapeutics have entered an exclusive global collaboration to develop and commercialize PTC124, PTC's late-stage oral therapy for the treatment of genetic disorders due to nonsense mutations.
Under the terms of…
Read More »
July 16, 2008
Novartis has extended its RNAi therapeutics collaboration with Alnylam Pharmaceuticals through October 2009. The alliance was initiated in October 2005 and is focused on the discovery, development, and commercialization of RNAi therapeutics toward a…
Read More »
July 14, 2008
Actelion has signed an agreement with GSK valued at as much as $3.3 billion to jointly develop and market Actelion's experimental sleeping pill candidate, almorexant. Actelion will receive an upfront payment of $148 million and $409 million upon regi…
Read More »
July 8, 2008
Patheon has been selected by SK Life Science, Inc., the US-based subsidiary of Korean SK Holdings, as its development services partner for two Central Nervous System (CNS) drug candidates. Patheon will provide formulation and analytical development s…
Read More »
July 8, 2008
Seattle Genetics has entered into an exclusive, worldwide collaboration agreement with Daiichi Sankyo for the development of antibody-drug conjugates (ADCs) targeting a single antigen found on multiple types of solid tumors.
…
Read More »
July 7, 2008
Althea Technologies, has signed a Letter of Intent to establish a complementary commercialization partnership with Protein'eXpert of Grenoble, France. The agreement provides access to Protein'eXpert's advanced protein engineering, process development…
Read More »
July 2, 2008
Catalent Pharma Solutions has entered into a joint marketing and collaboration agreement with One World Design and Manufacturing Group. Under the terms of the agreement, both companies will market One World's NextBottleT unit-dose compliance bottle t…
Read More »
July 1, 2008
AstraZeneca and Palatin have amended their January 2007 global licensing and research agreement to discover, develop and commercialize compounds targeting melanocortin receptors.
Under the amendment, Palatin has agreed to licen…
Read More »
July 1, 2008
Genmab has reached a development milestone for ofatumumab (HuMax-CD20) under the terms of its collaboration with GlaxoSmithKline. The milestone triggers a $6 million payment to Genmab as a result of the first patient treated in the Phase II study of…
Read More »
June 27, 2008
Schering-Plough and Merck withdrew the NDA for the Claritin (loratadine)/Singulair (montelukast) combination tablet. The companies also terminated the their respiratory joint venture formed in May 2000. The FDA issued a not-approvable letter in April…
Read More »
June 27, 2008
Exelixis and GlaxoSmithKline will end their six-year collaboration based on its success, on October 27, 2008, as scheduled. Under the terms of the collaboration, GSK has the right to select two compounds for further development and commercialization.…
Read More »
June 25, 2008
DSM Biologics and Crucell have entered into an agreement with Avid Bioservices to bring Avid into their Vendor Network. Under the terms of the agreement, Avid will be a pre-approved CMO for licensees of the PER.C6 cell line in the western U.S. Avid i…
Read More »
June 24, 2008
WuXi PharmaTech and Covance have entered into a Memorandum of Understanding to create a 50/50 joint venture to provide preclinical contract research services in China. Operations of the proposed joint venture will be located in a 323,450-sq.-ft., pur…
Read More »
June 20, 2008
Sigma-Aldrich has entered into a five-year collaboration to develop optimal cell lines for the production of monoclonal antibodies. Scientists at the University of California, San Francisco will lead the research into antibodies for a variety of canc…
Read More »
